Company Description
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide.
The company’s commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nighttime sleep disturbances; PONVORY to treat relapsing forms of multiple sclerosis; and NEREUSTM for preventing vomiting induced by motion.
It also develops Fanapt (iloperidone), a long acting injectable (LAI) formulation for the treatment of schizophrenia and hypertension; BysantiTM (milsaperidone), for the acute treatment of manic or mixed episodes associated with bipolar I disorder, and for the treatment of schizophrenia and major depressive disorder; HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, pediatric insomnia, delayed sleep phase disorder, and pediatric Non-24; PONVORY (ponesimod) to treat psoriasis and ulcerative colitis; and NEREUSTM (tradipitant) for prevention of vomiting induced by GLP-1 receptor agonists, as well as treatment of gastroparesis and atopic dermatitis.
In addition, the company’s products include Imsidolimab, an IL-36R antagonist to treat generalized pustular psoriasis; VTR-297, for the treatment of hematologic malignancies and onychomycosis, and several oncology indications; and VQW-765, small molecule alpha-7 nicotinic acetylcholine receptor partial agonist for the treatment of social/performance anxiety and psychiatric disorders.
Further, it develops cystic fibrosis transmembrane conductance regulator activators and inhibitors; and antisense oligonucleotide molecules.
The company was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
| Country | United States |
| Founded | 2002 |
| IPO Date | Apr 12, 2006 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 533 |
| CEO | Mihael Polymeropoulos |
Contact Details
Address: 2200 Pennsylvania Avenue NW, Suite 300E Washington, District of Columbia 20037 United States | |
| Phone | 202 734 3400 |
| Website | vandapharma.com |
Stock Details
| Ticker Symbol | VNDA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001347178 |
| CUSIP Number | 921659108 |
| ISIN Number | US9216591084 |
| Employer ID | 03-0491827 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Mihael H. Polymeropoulos M.D. | Founder, President, Chief Executive Officer and Chairman of The Board |
| Kevin Patrick Moran | Senior Vice President, Chief Financial Officer and Treasurer |
| Timothy Williams J.D. | Senior Vice President, General Counsel and Secretary |
| Joakim Wijkstrom | Senior Vice President and Chief Marketing Officer |
| Gunther Birznieks | Senior Vice President of Business Development |
| Scott L. Howell | Chief People Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 2, 2026 | 144 | Filing |
| Mar 2, 2026 | 144 | Filing |
| Mar 2, 2026 | 144 | Filing |
| Mar 2, 2026 | 144 | Filing |
| Mar 2, 2026 | 144 | Filing |
| Feb 23, 2026 | 144 | Filing |
| Feb 23, 2026 | 8-K | Current Report |
| Feb 19, 2026 | 8-K | Current Report |
| Feb 12, 2026 | S-3 | Registration statement under Securities Act of 1933 |
| Feb 12, 2026 | 10-K | Annual Report |